» Articles » PMID: 17521346

Prolonged Exposure to Levetiracetam Reveals a Presynaptic Effect on Neurotransmission

Overview
Journal Epilepsia
Specialty Neurology
Date 2007 May 25
PMID 17521346
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: The antiepileptic drug levetiracetam (LEV) is an enigma. Despite the fact that it specifically binds to the presynaptic vesicle protein, SV2A, no satisfactory mechanism of action has yet been identified. Using a combination of electrophysiological and cellular imaging techniques, we carefully tested the hypothesis that LEV directly interferes with neurotransmitter release.

Methods: We measured extracellular evoked responses in the CA1 region of rat hippocampal slices after paired pulse stimulation and after application of up to 10 pulses applied at 5-80 Hz. In parallel experiments, we used quantitative 2-photon microscopy and the fluorescent vesicular marker FM1-43 to measure the effect of repetitive stimulation on presynaptic vesicle release.

Results: Acute exposure to LEV (100 microM) had no effect on paired pulse synaptic responses. However, when slices were exposed to LEV for 3 h, there was a significant alteration in paired pulse responses and a more striking reduction in late synaptic potentials delivered in an 80 Hz train. LEV significantly reduced the rate of vesicle release assessed by FM1-43 destaining during 1 Hz stimulation.

Conclusion: LEV is unique among currently available antiepileptics, because it directly inhibits presynaptic neurotransmitter release in a use-dependent fashion. While there are alternate explanations for this observation, it is plausible that LEV exerts its effect by binding to a protein selectively expressed in presynaptic nerve terminals.

Citing Articles

Control of Synaptotagmin-1 Trafficking by SV2A-Mechanism and Consequences for Presynaptic Function and Dysfunction.

Hogg J, Cousin M J Neurochem. 2025; 169(1):e16308.

PMID: 39853744 PMC: 11758464. DOI: 10.1111/jnc.16308.


Disruption of adenosine metabolism increases risk of seizure-induced death despite decreased seizure severity.

Purnell B, Bhasin J, Rust B, George S, Bah K, Lu T Epilepsia. 2024; 65(9):2798-2811.

PMID: 39018000 PMC: 11534556. DOI: 10.1111/epi.18055.


Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil.

Wu P, Cao B, Tian F, Gao Z Neurosci Bull. 2023; 40(5):594-608.

PMID: 37897555 PMC: 11127901. DOI: 10.1007/s12264-023-01138-2.


Phenotypic screening using waveform analysis of synchronized calcium oscillations in primary cortical cultures.

Sakaguchi R, Nakamura S, Iha H, Tanaka M PLoS One. 2023; 18(4):e0271782.

PMID: 37115794 PMC: 10146483. DOI: 10.1371/journal.pone.0271782.


Short-Term and Long-Term Effects of Levetiracetam Monotherapy On Hematological Parameters in Children with Idiopathic Epilepsy.

Koc Ucar H, Sarigecili E, Bilen S, Sari S Sisli Etfal Hastan Tıp Bul. 2023; 57(1):46-53.

PMID: 37064851 PMC: 10098390. DOI: 10.14744/SEMB.2022.98523.